Previous 10 | Next 10 |
Strategic roadmap to achieve blockbuster status for multiple products and expand the Company’s engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vi...
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries PR Newswire Agreement between Ascendis Pharma A/S and ST is for the excl...
COPENHAGEN, Denmark, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice President & Chief Financial Officer, and Kennett Sprogøe, Ph.D., Executive Vice President, He...
2023-12-20 14:40:34 ET More on Ascendis Pharma Ascendis Pharma: Skytrofa Net Sales Not The Update Investors Are Waiting For Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript Ascendis Pharma signs license agreement with Teijin in Japan Ascendis recei...
TransCon CNP is the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children with achondroplasia COPENHAGEN, Denmark, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new analyses from...
– On primary efficacy and key secondary endpoints, TransCon hGH demonstrated statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo – TransCon hGH was generally safe and wel...
2023-12-11 12:51:40 ET More on Ascendis Pharma Ascendis Pharma: Skytrofa Net Sales Not The Update Investors Are Waiting For Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript Ascendis Pharma signs license agreement with Teijin in Japan Ascendis recei...
– PDUFA goal date is May 14, 2024 COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for Trans...
2023-11-29 05:05:37 ET More on Ascendis Pharma Ascendis Pharma: Skytrofa Net Sales Not The Update Investors Are Waiting For Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Ascendis receive...
– Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan – Ascendis Pharma is eligible to receive $70 million upfront, development/regulatory milesto...
News, Short Squeeze, Breakout and More Instantly...
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL , July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distributio...
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose • Improvements could not be explained by changes in linear growth only, supporti...
2024-06-19 21:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...